BusinessFibroGen to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016By Nasdaq OMXFeb 19, 2016, 12:00 PM UTC
BusinessFibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney DiseaseBy Nasdaq OMXFeb 16, 2016, 12:20 PM UTC
BusinessFibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXJan 6, 2016, 10:47 PM UTC
